Companies Related to "Receptor Tyrosine Protein Kinase ERBB Global Market Research" [Most Relevant Company Matches] RSS

11:08 EDT 21st September 2019 | BioPortfolio

Here are the most relevant search results for "Receptor Tyrosine Protein Kinase ERBB Global Market Research" found in our extensive corporate database of over 50,000 company records.

Showing "Receptor Tyrosine Protein Kinase ERBB Global Market Research" Companies 1–25 of 13,000+

Extremely Relevant

ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an in...

SGX Pharmaceuticals, Inc.

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelog...

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.


GloboZymes is a leading provider of top quality signal transduction enzymes, proteins and antibodies.We maintain a cell signaling, cancer and apoptosis-related research program. Our purified protein kinase, protein phosphatase, protein kinase substrate, modulator protein, protein synthesis initiation factor and affinity-purified antibody preparations generally exhibit greater than 90% homogeneity ...



Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...


KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California, with the purpose of supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets.The companys first products were the cutting edge protein kinase inhibitors...

Tyrosine Pharma, Inc.

Tyrosine Pharma, Inc., is a New Mexico-based biotech start-up company and a New Mexico Angels Technology Showcase Company. Visit for additional information.

Otava Ltd

OTAVA, Ltd. offers unique Receptor-Based Target-Focused libraries. These libraries are created from an extensive compound stock collection (490,000 compounds) and a rigorous process of refinement that involves harnessing the most current methods of theoretical medicinal chemistry. All of the Receptor-Based Target-Focused libraries of compounds are available in-house, and come with docking scores a...

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Global Market Insights, Inc.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients penetrative insights and actionable market data specially designed and presented to aid strategic decision making.

Raptor Pharmaceutical

Raptor Pharmaceutical Inc. is the culmination of years of experience and research by a consortium of scientists, investors, and creative minds with one common goal, the development of novel protein therapeutics directed at unmet medical needs. Raptor was incorporated in the State of Delaware on September 8, 2005. On January 27, 2006, Raptor purchased intellectual property pertaining to the researc...

Lundbeck Research USA, Inc.

Now that scientists have mapped the human genome, new opportunities exist for developing drugs that exclusively target specific receptors associated with the symptoms and causes of a disease.Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders. Lundbeck Research USA uses this discovery model to pursue n...

Carna Biosciences, Inc.

Carna Biosciences, Inc. (, founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, as well as providing drug discovery services to pharmaceutical companies, using proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development.


CEPTYR,® Inc., was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored domain in pharmaceutical development. We assembled the world’s leading experts in this field. Excellent progress has been made in identifying compelling PTP targets, and in novel chemistry for inhibitor drugs. Our first disease targeted is diabetes and obesity.

Transparency Market Research

Transparency Market Research (TMR) is a U.S.-based market intelligence company driven by a global team of high-pedigree industry consultants, analysts, and researchers. TMR leverages its worldwide Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those ...

Exelixis Inc.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly...

Medco Research Incorporated

Medco Research, Inc. is a pharmaceutical company dedicated to being a leader in the global commercialization of cardiovascular medicines and adenosine-receptor technologies leading to superior growth in shareholder value.

Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

PIramed Limited

PIramed was founded by Professor Michael Waterfield FRS (Ludwig Institute for Cancer Research, London), Professor Peter Parker (Cancer Research UK) and Professor Paul Workman (Institute of Cancer Research, London). To date, the Company has received £10m in equity and convertible loans from JPMorgan Partners and Merlin Biosciences.Principal intellectual property licences are to PI 3-kinase p110a (...

Receptos, Inc.

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR) therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The company’s lead program is a best-in-class S1P1 small molecule, agonist candidate for autoimmune indications, including multiple scler...


Protein Lounge is a leader in the field of system biology. We have developed many interactive web-based databases and software to help the life-scientists understand the complexity of systems biology. Systems biology efforts focus on understanding cellular networks, protein interactions involved in cell signaling, mechanisms of cell survival and apoptosis leading to development or identification o...

Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals is developing next generation anti-cancer drugs that target the molecular basis of disease. The Company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins.Protein kinases and phosphatases are families of proteins that are intimately involved in transmitting signals across the cell membrane. They cont...

More From BioPortfolio on "Receptor Tyrosine Protein Kinase ERBB Global Market Research"

Quick Search

Corporate Database Quicklinks